Please login to the form below

Not currently logged in
Email:
Password:

Kamada

This page shows the latest Kamada news and features for those working in and with pharma, biotech and healthcare.

Shire receives FDA nod for self-infusion of Glassia

Shire receives FDA nod for self-infusion of Glassia

Originally approved in 2010, Shire and partner Kamada's therapy is the only liquid, ready-to-use augmentation product for AAT deficiency currently on the market.

Latest news

  • Biologics buoyant

    52 . Kamada/Baxter. Glassia (liquid Alpha-1 Antitrypsin; AAT) – AAT deficiency (US, Canada, Australia and New Zealand)  . FDA approved. 45. Marina Biotech/Cypress Bioscience. Carbetocin (nasal oxytocin analogue)  - autism.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics